Business
Latigo raises USD 345.6m in upsized IPO backed by Nav1.8 Phase II data
Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a Thousand Oaks, California-based clinical-stage biopharmaceutical company whose lead Nav1.8 inhibitor recently...
Transcenta sells CDMO assets to WuXi Bio to focus on drug pipeline
Transcenta Holding Limited (HKEX: 6628) has agreed to sell its Hangzhou contract development and manufacturing organization assets to WuXi Biologics...
Actimed regains full control of S-oxprenolol after five-year partnership with Faraday
UK-based Actimed Therapeutics has reacquired full global rights to S-oxprenolol (ACM-002), an anabolic-catabolic transforming agent (ACTA) small molecule,...
Ensysce expands into neuroplastogenic pain with USD 77m Cy Biopharma acquisition
San Diego-based Ensysce Biosciences (Nasdaq: ENSC) has completed the acquisition of Cy Biopharma, a privately held clinical-stage company developing...
Tarsus builds retina franchise in USD 800 million Alkeus deal
Tarsus Pharmaceuticals (Nasdaq: TARS) has agreed to acquire Alkeus Pharmaceuticals, a privately held retinal disease biotech, for approximately USD 450...
Sophia Genetics expands AstraZeneca partnership with two cDX programs
Switzerland-based Sophia Genetics (Nasdaq: SOPH) has entered a multi-year global collaboration with AstraZeneca (NYSE: AZN) to develop, validate, and deploy...
BMS deploys Schrödinger's agentic AI platform across drug discovery
Schrödinger (Nasdaq: SDGR) and Bristol Myers Squibb announced a strategic software agreement to deploy Bunsen, Schrödinger's agentic AI co-scientist...
Braveheart Bio ups IPO pricing for USD 382.5m take-home
Braveheart Bio, Inc. (Nasdaq: BRVE), a San Francisco-based clinical-stage biopharmaceutical company developing a next-generation oral cardiac myosin...
Eli Lilly Q2'26: Retatrutide heads toward filing amid BLA dispute
Eli Lilly Q2 2026 earnings call, held on August 5, 2026, was dominated by the completion of the retatrutide Phase III registrational package and a contested...
Novo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances
Novo Nordisk A/S (NOVO) held its Q2 2026 earnings call on August 5, 2026, during which the Phase III failure of ziltivekimab in cardiovascular outcomes...
FAST taps Apertura's BBB-crossing AAV platform to advance Angelman gene therapy
The Foundation for Angelman Syndrome Therapeutics (FAST) has entered an agreement with New York-based Apertura Gene Therapy to access TfR1 CapX, a...
Eton taps China's Auson gel timolol for infantial hemangiomas
Deer Park, Illinois-based Eton Pharmaceuticals (Nasdaq: ETON) has licensed U.S. rights to ASN-001, a topical timolol gel for proliferating superficial...
CSPC and AstraZeneca establish biologics manufacturing joint venture in China
CSPC Pharmaceutical Group Limited (HKEX: 01093) and AstraZeneca announced a joint venture contract to construct and operate a new-generation biologics...
Attovia completes upsized IPO for USD 289m take-home
San Carlos, California-based Attovia Therapeutics, Inc. (Nasdaq: ATTO), a clinical-stage immunology company whose biparatopic biologics platform has...
Expedition raises USD 115m to advance Fosun-sourced DPP1 inhibitor
San Francisco-based Expedition Therapeutics has closed an oversubscribed USD 115 million Series B financing round to advance its lead asset, EXPD-101...
The AllSci Brief
Free, systematic R&D and deal news. Daily.